<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00782379</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000617648</org_study_id>
    <secondary_id>BMTGG-NSH-864</secondary_id>
    <nct_id>NCT00782379</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer</brief_title>
  <official_title>A Phase II Trial of Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched Peripheral Blood Stem Cells for Patients With Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northside Hospital, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northside Hospital, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving chemotherapy, such as fludarabine, busulfan, and cyclophosphamide, before a
      donor peripheral blood stem cell transplant helps stop the growth of cancer cells and helps
      stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem
      cells from a donor are infused into the patient they may help the patient's bone marrow make
      stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted
      cells from a donor can make an immune response against the body's normal cells. Giving
      high-dose cyclophosphamide together with tacrolimus and mycophenolate mofetil after
      transplant may stop this from happening.

      PURPOSE: This phase II trial is studying how well combination chemotherapy works when given
      together with a donor stem cell transplant, followed by tacrolimus, mycophenolate mofetil,
      and high-dose cyclophosphamide, in treating patients with high-risk hematologic cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To estimate the incidence of graft rejection and severe graft-versus-host disease after
           myeloablative HLA-mismatched peripheral blood stem cell transplantation (PBSCT) from
           first-degree relatives in patients with high-risk hematologic malignancies.

      Secondary

        -  To estimate overall survival, relapse, non-relapse mortality, and event-free survival in
           these patients.

        -  To characterize additional hematologic and non-hematologic toxicities of myeloablative
           haploidentical PBSCT.

        -  To characterize donor hematopoietic chimerism in peripheral blood stem cells after
           PBSCT.

      OUTLINE:

        -  Preparative regimen: Patients receive fludarabine phosphate IV over 30 minutes on days
           -7 to -2, busulfan IV over 3 hours on days -7 to -4, and cyclophosphamide IV over 1-2
           hours on days -3 and -2.

        -  Allogeneic peripheral blood stem cell transplantation (PBSCT): Patients undergo infusion
           of unmanipulated peripheral blood stem cells on day 0.

        -  Post-transplant regimen: Patients receive high-dose cyclophosphamide IV over 1-2 hours
           on days 3 and 4, tacrolimus IV over 24 hours or orally twice daily on days 5-180, and
           oral mycophenolate mofetil 3 times daily on days 5-34 followed by a taper to day 90.
           Treatment continues in the absence of disease progression or clinically significant
           graft-vs-host disease.

      After completion of PBSCT, patients are followed periodically for 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Graft Rejection for Patients at Day 100</measure>
    <time_frame>Day 100</time_frame>
    <description>Number of patients who experienced graft rejection by Day 100</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients Who Experienced Severe Graft-versus-host Disease (GVHD)(Grade 3 or 4)</measure>
    <time_frame>Day 100</time_frame>
    <description>Number of patients who experienced post-transplant complication (GVHD) as seen by clinical evidence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival at Day 100</measure>
    <time_frame>Day 100</time_frame>
    <description>Overall survival is assessed, without regard to disease status, post-transplant, at Day 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse Mortality at 1 Year After Peripheral Blood Stem Cell Transplantation (PBSCT)</measure>
    <time_frame>1 year</time_frame>
    <description>Non-relapse mortality refers to whether a patient dies of causes related to something other than the primary disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement of &gt;90% (Full) Donor Chimerism in the T-Cell Lineage as Measured by PCR at Day 30 Post-transplantation</measure>
    <time_frame>Day 30</time_frame>
    <description>Chimerism analysis of peripheral blood mononuclear cells using PCR (polymerase chain reaction) for STR/VNTR (short tandme repeat/variable number tandem repeat) will be performed post transplant. On each occasion, the peripheral blood will be separated into the T-cell component (using e.g. CD3 selection) and the myeloid component (using e.g.CD14/15 selection) before assessment of chimerism.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse Mortality at Day 100 After Peripheral Blood Stem Cell Transplantation (PBSCT)</measure>
    <time_frame>Day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement of &gt;90% (Full) Donor Chimerism in the T-Cell Lineage as Measured by PCR at Day 60 Post-transplantation</measure>
    <time_frame>Day 60</time_frame>
    <description>Chimerism analysis of peripheral blood mononuclear cells using PCR for STR/VNTR will be performed post transplant. On each occasion, the peripheral blood will be separated into the T-cell component (using e.g. CD3 selection) and the myeloid component (using e.g.CD14/15 selection) before assessment of chimerism.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement of &gt;90% (Full) Donor Chimerism in the T-Cell Lineage as Measured by PCR at Day 90 Post-transplantation</measure>
    <time_frame>Day 90</time_frame>
    <description>Chimerism analysis of peripheral blood mononuclear cells using PCR for STR/VNTR will be performed post transplant. On each occasion, the peripheral blood will be separated into the T-cell component (using e.g. CD3 selection) and the myeloid component (using e.g.CD14/15 selection) before assessment of chimerism.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival at 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>Overall survival, defined as a patient being alive after transplant, is without regard to disease status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival at 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>Disease free survival refers to patients with no evidence of disease after transplant, at the 12 month time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival at Day 100</measure>
    <time_frame>Day 100</time_frame>
    <description>Disease free survival refers to patients with no evidence of disease after transplant, at the Day 100 time point.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Myeloablative Haploidentical Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive treatment using Fludarabine, Busulfan and Cyclophosphamide prior to receiving a haploidentical transplant followed by post-transplant cyclosphosphamide.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <description>110 mg/m2 infused over 3 hours once daily on 4 consecutive days (Days -7, -6, -5, -4)</description>
    <arm_group_label>Myeloablative Haploidentical Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>14.5 mg/kg infused over 1-2 hours once daily on 2 consecutive days (days -3,-2).</description>
    <arm_group_label>Myeloablative Haploidentical Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <description>30mg/m2 infused over 30 minutes once daily on three consecutive days (days -5, -4, -3)</description>
    <arm_group_label>Myeloablative Haploidentical Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
    <description>15 mg/kg po three times a daily with a maximum dose of 3gm/day starting D+5. To be discontinued on Day +35 in the absence of clinically significant GVHD.</description>
    <arm_group_label>Myeloablative Haploidentical Transplant</arm_group_label>
    <other_name>CellCept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
    <description>0.03 mg/kg/day infuse over 24 hours starting on day +5 (adjusted to maintain trough level of 5-15 ng/ml). Switch to oral (twice daily divided dose) on day +21 or when able to tolerate PO. Discontinue on day +180 in the absence of clinically significant GVHD.</description>
    <arm_group_label>Myeloablative Haploidentical Transplant</arm_group_label>
    <other_name>Prograf, FK-506</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic hematopoietic stem cell transplantation</intervention_name>
    <description>Patients to received unmanipulated PBSCs on Day 0</description>
    <arm_group_label>Myeloablative Haploidentical Transplant</arm_group_label>
    <other_name>Allo HSCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <description>patients to receive unmanipulated PBSCs on day 0</description>
    <arm_group_label>Myeloablative Haploidentical Transplant</arm_group_label>
    <other_name>allogeneic hematopoietic stem cell transplant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of one of the following high-risk hematologic malignancies:

               -  Chronic myelogenous leukemia meeting one of the following criteria:

                    -  Disease in chronic phase and resistant to available tyrosine kinase
                       inhibitors

                    -  Disease in accelerated phase

                    -  Disease with blast crisis that has entered into a second chronic phase after
                       induction chemotherapy

               -  Acute myelogenous leukemia meeting the following criteria:

                    -  Marrow blasts &lt; 5% but persistence of minimal residual disease by flow
                       cytometry, cytogenetics, or FISH

                    -  Must meet one of the following criteria:

                         -  Disease in second or subsequent complete remission

                         -  Primary induction chemotherapy failure with disease subsequently
                            entering complete remission

                         -  Disease in first complete remission with poor-risk cytogenetics or
                            arising from preceding hematological disease

               -  Myelodysplastic syndrome meeting at least one of the following criteria:

                    -  Treatment-related

                    -  Monosomy 7 or complex cytogenetics

                    -  International prognostic scoring system score ≥ 1.5

                    -  Chronic myelomonocytic leukemia

               -  Acute lymphocytic leukemia or lymphoblastic lymphoma meeting the following
                  criteria:

                    -  Marrow blasts &lt; 5% but persistence of minimal residual disease by flow
                       cytometry, cytogenetics, or FISH

                    -  Must meet one of the following criteria:

                         -  Disease in second or subsequent complete remission

                         -  Acute lymphocytic leukemia with poor-risk karyotype [e.g., t(9;22) or
                            bcr-abl fusion, t(4;11), or other MLL translocation] and in first
                            complete remission

               -  Chronic lymphocytic leukemia or prolymphocytic leukemia meeting both of the
                  following criteria:

                    -  Previously treated disease that has either relapsed or failed to respond
                       adequately to conventional-dose therapy including purine analogs

                    -  In the opinion of the transplant physician, unlikely to benefit from reduced
                       intensity transplantation due to the presence of one or more high-risk
                       features (i.e., bulky tumor masses, B symptoms, and/or inadequate response
                       to salvage chemotherapy)

               -  Hodgkin or non-Hodgkin lymphoma (including low-grade, mantle cell, and
                  intermediate-grade/diffuse disease) meeting the following criteria:

                    -  Previously treated disease that has either relapsed or failed to respond
                       adequately to conventional-dose therapy or autologous transplantation

                    -  In the opinion of the transplant physician, unlikely to benefit from reduced
                       intensity transplantation due to the presence of one or more high-risk
                       features (i.e., bulky tumor masses, B symptoms, and/or inadequate response
                       to salvage chemotherapy) NOTE: A new classification scheme for adult
                       non-Hodgkin lymphoma has been adopted by PDQ. The terminology of &quot;indolent&quot;
                       or &quot;aggressive&quot; lymphoma will replace the former terminology of &quot;low&quot;,
                       &quot;intermediate&quot;, or &quot;high&quot; grade lymphoma. However, this protocol uses the
                       former terminology.

          -  No available matched related or unrelated donor OR a matched related or unrelated
             donor will not be available in the time frame necessary to perform a transplant

          -  Availability of a first-degree relative (parent, child, sibling) matched at 3/6-5/6
             loci (HLA-A, -B, -DR)

               -  Donor must be willing to donate mobilized peripheral blood stem cells

               -  No positive HLA crossmatch in the host-vs-graft direction or high titer
                  donor-specific antibodies

        PATIENT CHARACTERISTICS:

          -  Karnofsky performance status 70-100%

          -  Bilirubin &lt; 2 mg/dL (unless due to hemolysis, Gilbert syndrome, or primary malignancy)

          -  Creatinine &lt; 2 mg/dL OR creatinine clearance ≥ 40 mL/min

          -  Not pregnant

          -  Fertile patients must use effective contraception

          -  LVEF (Left ventriculr ejection fraction) ≥ 45%

          -  FEV_1 and forced vital capacity ≥ 50% predicted

          -  No HIV positivity

          -  No debilitating medical or psychiatric illness that would preclude giving informed
             consent or receiving optimal treatment and follow-up

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No immunosuppressive agents ≤ 24 hours after completion of post-transplant
             cyclophosphamide (including steroids as antiemetics)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott R. Solomon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Blood and Marrow Transplant Group of Georgia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>H. Kent Holland, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Blood and Marrow Transplant Group of Georgia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Asad Bashey, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Blood and Marrow Transplant Group of Georgia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lawrence E. Morris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Blood and Marrow Transplant Group of Georgia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Blood and Marrow Transplant Group of Georgia</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2008</study_first_submitted>
  <study_first_submitted_qc>October 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2008</study_first_posted>
  <results_first_submitted>March 18, 2013</results_first_submitted>
  <results_first_submitted_qc>March 18, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 3, 2013</results_first_posted>
  <last_update_submitted>October 28, 2013</last_update_submitted>
  <last_update_submitted_qc>October 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III adult Hodgkin lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
  <keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II mantle cell lymphoma</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>prolymphocytic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were consented between 12/17/08 through 01/13/11. The transplants occured between 1/13/09 and 3/2/11</recruitment_details>
      <pre_assignment_details>NA - this study did not use group assignments. All patients received the same preparative regimen consisting of Fludarabine 25 mg/m2 x 5 days, busulfan 110 mg/m2 x4 days, cyclophosphamide 14.5 mg x 2 days PRE transplant and cyclophosphamide 50 mg x2 days POST transplant</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Haploidentical Transplant</title>
          <description>Patients receiving Fludarabine, Busulfan, cyclophosphamide and post-transplant cyclophosphamide for a haploidentical donor transplant</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Haploidentical Transplant</title>
          <description>Patients receiving Fludarabine, Busulfan, cyclophosphamide and post-transplant cyclophosphamide for a haploidentical donor transplant</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.75" spread="8.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Graft Rejection for Patients at Day 100</title>
        <description>Number of patients who experienced graft rejection by Day 100</description>
        <time_frame>Day 100</time_frame>
        <population>20 patients were treated and able to be analyzed for graft rejection</population>
        <group_list>
          <group group_id="O1">
            <title>Haploidentical Transplant</title>
            <description>Patients receiving Fludarabine, Busulfan, cyclophosphamide and post-transplant cyclophosphamide for a haploidentical donor transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Graft Rejection for Patients at Day 100</title>
          <description>Number of patients who experienced graft rejection by Day 100</description>
          <population>20 patients were treated and able to be analyzed for graft rejection</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Who Experienced Severe Graft-versus-host Disease (GVHD)(Grade 3 or 4)</title>
        <description>Number of patients who experienced post-transplant complication (GVHD) as seen by clinical evidence</description>
        <time_frame>Day 100</time_frame>
        <population>17 patients were alive at Day 100 and eligible to be evaluated for grade 3-4 graft versus host disease</population>
        <group_list>
          <group group_id="O1">
            <title>Haploidentical Transplant</title>
            <description>Patients receiving Fludarabine, Busulfan, cyclophosphamide and post-transplant cyclophosphamide for a haploidentical donor transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Experienced Severe Graft-versus-host Disease (GVHD)(Grade 3 or 4)</title>
          <description>Number of patients who experienced post-transplant complication (GVHD) as seen by clinical evidence</description>
          <population>17 patients were alive at Day 100 and eligible to be evaluated for grade 3-4 graft versus host disease</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival at Day 100</title>
        <description>Overall survival is assessed, without regard to disease status, post-transplant, at Day 100.</description>
        <time_frame>Day 100</time_frame>
        <population>20 patients received a haploidentical transplant and therefore are eligible to be evaluated for Day 100 survival</population>
        <group_list>
          <group group_id="O1">
            <title>Haploidentical Transplant</title>
            <description>Patients receiving Fludarabine, Busulfan, cyclophosphamide and post-transplant cyclophosphamide for a haploidentical donor transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival at Day 100</title>
          <description>Overall survival is assessed, without regard to disease status, post-transplant, at Day 100.</description>
          <population>20 patients received a haploidentical transplant and therefore are eligible to be evaluated for Day 100 survival</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-relapse Mortality at 1 Year After Peripheral Blood Stem Cell Transplantation (PBSCT)</title>
        <description>Non-relapse mortality refers to whether a patient dies of causes related to something other than the primary disease.</description>
        <time_frame>1 year</time_frame>
        <population>6 patients died prior to one year and therefore are eligible to be evaluated for non-relapse mortality.</population>
        <group_list>
          <group group_id="O1">
            <title>Haploidentical Transplant</title>
            <description>Patients receiving Fludarabine, Busulfan, cyclophosphamide and post-transplant cyclophosphamide for a haploidentical donor transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Non-relapse Mortality at 1 Year After Peripheral Blood Stem Cell Transplantation (PBSCT)</title>
          <description>Non-relapse mortality refers to whether a patient dies of causes related to something other than the primary disease.</description>
          <population>6 patients died prior to one year and therefore are eligible to be evaluated for non-relapse mortality.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Achievement of &gt;90% (Full) Donor Chimerism in the T-Cell Lineage as Measured by PCR at Day 30 Post-transplantation</title>
        <description>Chimerism analysis of peripheral blood mononuclear cells using PCR (polymerase chain reaction) for STR/VNTR (short tandme repeat/variable number tandem repeat) will be performed post transplant. On each occasion, the peripheral blood will be separated into the T-cell component (using e.g. CD3 selection) and the myeloid component (using e.g.CD14/15 selection) before assessment of chimerism.</description>
        <time_frame>Day 30</time_frame>
        <population>18 patients had Day 30 chimerism drawn</population>
        <group_list>
          <group group_id="O1">
            <title>Haploidentical Transplant</title>
            <description>Patients receiving Fludarabine, Busulfan, cyclophosphamide and post-transplant cyclophosphamide for a haploidentical donor transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Achievement of &gt;90% (Full) Donor Chimerism in the T-Cell Lineage as Measured by PCR at Day 30 Post-transplantation</title>
          <description>Chimerism analysis of peripheral blood mononuclear cells using PCR (polymerase chain reaction) for STR/VNTR (short tandme repeat/variable number tandem repeat) will be performed post transplant. On each occasion, the peripheral blood will be separated into the T-cell component (using e.g. CD3 selection) and the myeloid component (using e.g.CD14/15 selection) before assessment of chimerism.</description>
          <population>18 patients had Day 30 chimerism drawn</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-relapse Mortality at Day 100 After Peripheral Blood Stem Cell Transplantation (PBSCT)</title>
        <time_frame>Day 100</time_frame>
        <population>2 patients died before Day 100 and therefore are eligible to be evaluated for non-relapse mortality</population>
        <group_list>
          <group group_id="O1">
            <title>Haploidentical Transplant</title>
            <description>Patients receiving Fludarabine, Busulfan, cyclophosphamide and post-transplant cyclophosphamide for a haploidentical donor transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Non-relapse Mortality at Day 100 After Peripheral Blood Stem Cell Transplantation (PBSCT)</title>
          <population>2 patients died before Day 100 and therefore are eligible to be evaluated for non-relapse mortality</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Achievement of &gt;90% (Full) Donor Chimerism in the T-Cell Lineage as Measured by PCR at Day 60 Post-transplantation</title>
        <description>Chimerism analysis of peripheral blood mononuclear cells using PCR for STR/VNTR will be performed post transplant. On each occasion, the peripheral blood will be separated into the T-cell component (using e.g. CD3 selection) and the myeloid component (using e.g.CD14/15 selection) before assessment of chimerism.</description>
        <time_frame>Day 60</time_frame>
        <population>18 patients had chimerism drawn at Day 60</population>
        <group_list>
          <group group_id="O1">
            <title>Haploidentical Transplant</title>
            <description>Patients receiving Fludarabine, Busulfan, cyclophosphamide and post-transplant cyclophosphamide for a haploidentical donor transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Achievement of &gt;90% (Full) Donor Chimerism in the T-Cell Lineage as Measured by PCR at Day 60 Post-transplantation</title>
          <description>Chimerism analysis of peripheral blood mononuclear cells using PCR for STR/VNTR will be performed post transplant. On each occasion, the peripheral blood will be separated into the T-cell component (using e.g. CD3 selection) and the myeloid component (using e.g.CD14/15 selection) before assessment of chimerism.</description>
          <population>18 patients had chimerism drawn at Day 60</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Achievement of &gt;90% (Full) Donor Chimerism in the T-Cell Lineage as Measured by PCR at Day 90 Post-transplantation</title>
        <description>Chimerism analysis of peripheral blood mononuclear cells using PCR for STR/VNTR will be performed post transplant. On each occasion, the peripheral blood will be separated into the T-cell component (using e.g. CD3 selection) and the myeloid component (using e.g.CD14/15 selection) before assessment of chimerism.</description>
        <time_frame>Day 90</time_frame>
        <population>13 patients had chimerism drawn at Day 90</population>
        <group_list>
          <group group_id="O1">
            <title>Haploidentical Transplant</title>
            <description>Patients receiving Fludarabine, Busulfan, cyclophosphamide and post-transplant cyclophosphamide for a haploidentical donor transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Achievement of &gt;90% (Full) Donor Chimerism in the T-Cell Lineage as Measured by PCR at Day 90 Post-transplantation</title>
          <description>Chimerism analysis of peripheral blood mononuclear cells using PCR for STR/VNTR will be performed post transplant. On each occasion, the peripheral blood will be separated into the T-cell component (using e.g. CD3 selection) and the myeloid component (using e.g.CD14/15 selection) before assessment of chimerism.</description>
          <population>13 patients had chimerism drawn at Day 90</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival at 12 Months</title>
        <description>Overall survival, defined as a patient being alive after transplant, is without regard to disease status.</description>
        <time_frame>12 months</time_frame>
        <population>20 patients received haploidentical transplant and therefore were eligible to be evaluated for overall survival at 1 year</population>
        <group_list>
          <group group_id="O1">
            <title>Haploidentical Transplant</title>
            <description>Patients receiving Fludarabine, Busulfan, cyclophosphamide and post-transplant cyclophosphamide for a haploidentical donor transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival at 12 Months</title>
          <description>Overall survival, defined as a patient being alive after transplant, is without regard to disease status.</description>
          <population>20 patients received haploidentical transplant and therefore were eligible to be evaluated for overall survival at 1 year</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Free Survival at 12 Months</title>
        <description>Disease free survival refers to patients with no evidence of disease after transplant, at the 12 month time point.</description>
        <time_frame>12 months</time_frame>
        <population>14 patients were alive at one year and therefore were eligible to be evaluated for disease free survival at 1 year</population>
        <group_list>
          <group group_id="O1">
            <title>Haploidentical Transplant</title>
            <description>Patients receiving Fludarabine, Busulfan, cyclophosphamide and post-transplant cyclophosphamide for a haploidentical donor transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Free Survival at 12 Months</title>
          <description>Disease free survival refers to patients with no evidence of disease after transplant, at the 12 month time point.</description>
          <population>14 patients were alive at one year and therefore were eligible to be evaluated for disease free survival at 1 year</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Free Survival at Day 100</title>
        <description>Disease free survival refers to patients with no evidence of disease after transplant, at the Day 100 time point.</description>
        <time_frame>Day 100</time_frame>
        <population>17 patients were alive at Day 100 and therefore were eligible to be evaluated for disease free survival at D100</population>
        <group_list>
          <group group_id="O1">
            <title>Haploidentical Transplant</title>
            <description>Patients receiving Fludarabine, Busulfan, cyclophosphamide and post-transplant cyclophosphamide for a haploidentical donor transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Free Survival at Day 100</title>
          <description>Disease free survival refers to patients with no evidence of disease after transplant, at the Day 100 time point.</description>
          <population>17 patients were alive at Day 100 and therefore were eligible to be evaluated for disease free survival at D100</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse Events (AEs) regardless of grade were recorded for 6mo post-transplant. Serious Adverse Events (SAEs) were reported within 24hrs of notification. Patients with baseline AE that did not experience an increase in grade (remained the same grade or lesser)were not included in the totals.</desc>
      <group_list>
        <group group_id="E1">
          <title>Haploidentical Transplant</title>
          <description>Patients receiving Fludarabine, Busulfan, cyclophosphamide and post-transplant cyclophosphamide for a haploidentical donor transplant</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title vocab="CTCAE 3.0">Death</sub_title>
                <description>This event is death as it relates to being a serious adverse event (rather than all deaths for the study)</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute graft versus host disease</sub_title>
                <description>Acute graft versus host disease as it relates to SAE reporting rather than the total number of patients who had GVHD</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BK virus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypoglycemia induced hemiparesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhagic Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANC</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>edema</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>fluid overload</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>hyperkalemia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>hypermagnesemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>hypernatremia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>increased PT</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>LE edema</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>thrombocytopenia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Decreased WBC</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>bradycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>cardiomyopathy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>decreased EF</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>tachycardia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>hearing loss</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>dry eyes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>periorbital edema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>visual changes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal cramping</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>abdominal distension</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>abdominal tenderness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>abnormal taste</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Altered taste</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>bloating</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>difficulty swallowing</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>esophagitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>flatulence</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>GERD/dyspepsia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>GI distress</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>increased oral secretions</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>mucositis</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>rectal discomfort</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>sore throat</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>stool incontinence</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>throat pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>vomitting</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional - feeling cold</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>chills</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>drowsiness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>epistaxis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>general deconditioning</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>hiccoughs</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>lethargy</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>neutropenic fever</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>night sweats</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>restlessness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>rigors</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>suprapubic pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>unsteady gait</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>weakness</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>weight gain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>weight loss</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>ALT</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>AST</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>hives</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>seasonal allergies</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BK virus</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>c-diff</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>CMV</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Coag Neg Staph</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>gram + bacteremia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>MRSE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>parainfluenza</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>RSV</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>staph epi</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>thrush</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>VRE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>hypercalcemia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="11" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>hyperphosphatemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>hypoalbuminemia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>hypocalcemia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>hypoglycemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>hypokalemia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>hypomagnesemia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>hyponatremia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>hypophosphatemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ALK PHOS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Anorexia/decreased appetite</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>myalgia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>neck pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>neck stiffness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>shoulder discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>agitation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>peripheral neuropathy</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>tremors</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>confusion</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>depression</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>flat affect</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>hallucinations</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Bladder pressure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>bladder spasms</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>creatinine</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>hematuria</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>hemorrhagic cystitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>renal insufficiency</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>urinary burning</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>urinary frequency</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>urinary incontinence</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>urinary urgency</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>penile pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>vaginal spotting/bleeding</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Alveolar hemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>hemoptysis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>hypoxia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>nasal congestion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>pleural effusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>pulmonary infiltrates</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>reactive airway disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>respiratory failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>rhinorrhea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>shortness of breath</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>sinus congestion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>sinus drainage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>sinusitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>tachypnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>wheezing</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>bruising</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>cvc bleeding</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>cvc erythema</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>cvc tenderness/pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>diaphoresis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>dry lips</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>dry skin</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>erythema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>facial edema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>hemorrhoids</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>hyperpigmented skin</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>hypopigmentation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>lip lesion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>pruritis</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>skin discoloration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>skin tear</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Scott Solomon</name_or_title>
      <organization>Blood and Marrow Transplant Group of Georgia</organization>
      <phone>404-255-1930</phone>
      <email>ssolomon@bmtga.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

